This study, carried out in kidney and bladder cancer cell lines, established the paradigm in which LPA (and other GPCR agonists) can induce the release of EGFR ligands that activate EGFR in an autocrine manner. This evidence concerns the gene EGFR and urinary bladder carcinoma.